05th week of 2013 patent applcation highlights part 50 |
Patent application number | Title | Published |
20130029922 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, PACLITAXEL, AND ASPIRIN - The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity. | 2013-01-31 |
20130029923 | Materials and Methods for Prevention and Treatment of Viral Infections - The subject invention provides a novel and advantageous method for preventing and treating viral infection. Specifically exemplified herein are therapeutic uses of forsythoside A and jacaranone, compounds isolated from traditional Chinese medicinal material such as | 2013-01-31 |
20130029924 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF - Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases. | 2013-01-31 |
20130029925 | Method for Preventing Cancer Metastasis - The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis. | 2013-01-31 |
20130029926 | COMPOSITIONS AND METHODS FOR DETERMING CANCER SUSCEPTIBILITY - The invention generally relates to a molecular classification of disease and particularly to molecular markers for cancer susceptibility and methods of use thereof. More specifically, the invention relates to the determination, screening, or classification of an individual's genetic risk for breast and ovarian cancer susceptibility. | 2013-01-31 |
20130029927 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 2013-01-31 |
20130029928 | COMPOSITIONS COMPRISING PERFLUOROOCTANOIC ACID - There is provided compositions comprising perfluorooctanoic acid (PFOA) or a salt, derivative or variant thereof. There is also provided uses, methods therapeutic systems and combination therapies relating to PFOA. | 2013-01-31 |
20130029929 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2013-01-31 |
20130029930 | ACTIVATION AND ACTIVATORS OF SIRT6 - The invention provides a method of increasing a deacetylated activity of SIRT6 by contacting SIRT6 with an agent that binds SIRT6 and reduces the K | 2013-01-31 |
20130029931 | PLEUROTUS TUBER-REGIUM POLYSACCHARIDE FUNCTIONALIZED NANO-SELENIUM HYDROSOL WITH ANTI-TUMOR ACTIVITY AND PREPARATION METHOD THEREOF - The preparation of | 2013-01-31 |
20130029932 | COMPOSITION FOR EXTERNAL USE ON SKIN, COSMETIC, AND CLEANING AGENT - A composition for external use on skin that can be spread evenly on the skin, does not produce a liquid residue as a result of temperature change, and can suppress a feeling of sliminess of xanthan gum is provided. There are provided a composition for external use on skin containing 0.1% by mass to 10% by mass of a component (A) (a water-soluble polymer obtained by mixing agar with xanthan gum) and 30% by mass or more of a component (D) (water); the composition for external use on skin containing 0.5% by mass to 40% by mass of a divalent polyol as a component (B); the composition for external use on skin according to any one of the above compositions, which contains moisturizers as a component (C); and the composition for external use on skin according to any one of the above compositions, which contains oil as a component (E). | 2013-01-31 |
20130029933 | Hydrogel for Natural Cosmetic Purposes - The subject matter of the present invention is a hydrogel which includes a combination of at least four polysaccharides. These polysaccharides are those which are in the natural state and which are not produced, altered or modified by chemical reactions. The combination of konjac mannan, xanthan gum, pullulan and carrageenan and optionally sclerotium gum produces, within certain concentration ranges, a stable, slightly sticky, neutral smelling, flexible and transparent hydrogel which can be used as a cosmetic product for skin care. | 2013-01-31 |
20130029934 | SILYL-DERIVATIVES OF POLYSACCHARIDES - The present invention relates to novel silyl-derivatives of polysaccharides and their salts, the processes for their preparation and their use in cosmetic/pharmaceutical field. | 2013-01-31 |
20130029935 | MINERAL AMINO ACID POLYSACCHARIDE COMPLEX - This document provides complexes comprising a mineral-amino acid compound and a polysaccharide. For example, the document provides compositions containing such complexes and methods of making and using such complexes. | 2013-01-31 |
20130029936 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same - The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis. | 2013-01-31 |
20130029937 | TREATMENT OF SURFACTANTS - The invention relates to a method for enhancing a surfactant, in particular a pulmonary surfactant, as well as a method for producing a surfactant enhancement agent, in particular a pulmonary surfactant enhancement agent. The invention also relates to a surfactant enhancement agent and a use of an enhancement agent for enhancing a surfactant, in particular, a pulmonary surfactant. Further, the invention relates to a method of mitigating oxidative damage to pulmonary surfactant by adding a cholesterol-sequestrating agent such as cyclodextrin. Finally, a method is provided for treating a patient having surfactant dysfunction due to oxidative damage to pulmonary surfactant by administering a surfactant-protective amount of a cholesterol-sequestrating agent to protect the surfactant from the negative effects of oxidative degradation. In the examples we show that MβCD, a cholesterol-sequestrating agent, can restore dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non CF bronchiolitis to normal function. | 2013-01-31 |
20130029938 | Chemical Compounds - Compounds of Formula I and methods for treating metabolic disorders are disclosed. | 2013-01-31 |
20130029939 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R | 2013-01-31 |
20130029940 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS - There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus. | 2013-01-31 |
20130029941 | 7,11-METHANOCYCLOOCTA [B] QUINOLINE DERIVATIVE AS HIGHLY FUNCTIONALIZABLE ACETYLCHOLINESTERASE INHIBITORS - New highly functionalizable Huprine derivatives of formula I: | 2013-01-31 |
20130029942 | COMPOUNDS AND THERAPEUTICAL USES THEREOF - Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. | 2013-01-31 |
20130029943 | Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries - The present invention relates to novel chemistries which allow for heretofore unobtainable substituted tetracycline compounds which exhibit significant activity in tetracycline responsive states. The methods disclosed herein utilize reactive tetracycline-based precursor compounds, reactive organic substituent precursors and transition metal catalysts under conditions such that a tetracycline compound substituted with the desired organic substituent is formed. In one embodiment of the invention, a substituted tetracycline compound may be prepared by combining a reactive tetracycline-based precursor compound such as an arene tetracycline diazonium salt, and a reactive organic substituent precursor, e.g., alkenes, substituted alkenes, vinyl monomers, aromatics and heteroaromatics, in the presence of a transition metal catalyst, such as palladium chloride, under conditions such that a tetracycline compound substituted with the organic substituent is formed. Such compounds may optionally act as intermediates for making other compounds, e.g., hydrogenation of unsaturated groups on the substituent. | 2013-01-31 |
20130029944 | INHIBITORS OF PROTEIN KINASES - The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. | 2013-01-31 |
20130029945 | Darunavir Polymorph and Process for Preparation Thereof - There is disclosed crystalline darunavir hydrate substantially free of any non-aqueous solvent. | 2013-01-31 |
20130029946 | DISSOLUTION OF ARTERIAL PLAQUE - Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 μM are achieved; in some embodiments levels ranging from about 100 μM to about 600 μM are achieved; in some embodiments, levels ranging from about 100 μM to about 300 μM are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier. | 2013-01-31 |
20130029947 | PROGESTERONE CONTAINING ORAL DOSAGE FORMS AND KITS - The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C | 2013-01-31 |
20130029948 | HETEROCYCLIC AUTOTAXIN INHIBITORS AND USES THEREOF - Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases. | 2013-01-31 |
20130029949 | Substituted Quinolines and Their Use As Medicaments - Disclosed are substituted quinolines of formula 1 | 2013-01-31 |
20130029950 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE VASCULAR DISORDERS - The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine. | 2013-01-31 |
20130029951 | Combination of Azelastine and Ciclesonide for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 2013-01-31 |
20130029952 | Combination of Azelastine and Mometasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 2013-01-31 |
20130029953 | PROGESTERONE ANTAGONISTS - Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds. | 2013-01-31 |
20130029954 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS. In particular, the following compounds are provided herein, including pharmaceutically acceptable salts thereof: | 2013-01-31 |
20130029955 | INHIBITORS OF GALECTIN-3 AND METHODS OF USE THEREOF - Described herein are methods and compositions for inhibiting galectin-3 in a subject. Also described are methods and compositions for treating heart failure. | 2013-01-31 |
20130029956 | NEW METHOD - The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer. | 2013-01-31 |
20130029957 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 2013-01-31 |
20130029958 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 2013-01-31 |
20130029959 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand. | 2013-01-31 |
20130029960 | ENHANCED BONE HEALING - The combined use—whether by adsorption or covalent linkage—of Melatonin adjacent any bone implant or graft, preferably any calcium- and oxide-containing artificial bone graft material, and more preferably a calcium aluminate composition. Alternatively, the bone graft or implant material may be used as a scaffold for tissue engineering. | 2013-01-31 |
20130029961 | Substituted Heterocyclic Aza Compounds - Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders. | 2013-01-31 |
20130029962 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders. | 2013-01-31 |
20130029963 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES - According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A | 2013-01-31 |
20130029964 | [5, 6] HETEROCYCLIC COMPOUND - An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R | 2013-01-31 |
20130029965 | PHARMACEUTICAL SOLID DISPERSIONS - A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%. | 2013-01-31 |
20130029966 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R | 2013-01-31 |
20130029967 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors - There is provided compounds of formula (I), wherein A | 2013-01-31 |
20130029968 | INDAZOLES - The present invention relates to compounds of formula (I): | 2013-01-31 |
20130029969 | HETEROCYCLIC COMPOUND - Provided is a compound useful for the prophylaxis or treatment of cancer. | 2013-01-31 |
20130029970 | CB Receptor Agonists - The present disclosure relates to compounds of formula I useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders. | 2013-01-31 |
20130029971 | CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I): | 2013-01-31 |
20130029972 | NOTCH PATHWAY SIGNALING INHIBITOR COMPOUND - The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer. | 2013-01-31 |
20130029973 | TETRAHYDROBENZOTHIOPHENE COMPOUND - A compound has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating hyperphosphatemia, preventing hyperphosphatemia, or both. The compound is a tetrahydrobenzothiophene compound. A pharmaceutical composition for treating hyperphosphatemia includes the compound or salt thereof. A method of treating hyperphosphatemia includes administering to a subject an effective amount of the compound or salt thereof. | 2013-01-31 |
20130029974 | 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS - There are provided 3,5-disubstituted derivatives of 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one compounds of formula (I) or a pharmaceutically acceptable salt thereof as defined in the present specification, which modulate the activity of protein kinases. The compounds are therefore useful in treating diseases caused by dysregulated protein kinase activity. In particular, such diseases to be treated with a compound of formula (I) of the present invention is one caused by and/or associated with disregulated protein kinase activity selected from the group consisting of cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders. The present invention also relates to processes for preparing the compounds of formula (I), combinatorial libraries thereof, pharmaceutical compositions comprising them, and methods of treating diseases utilizing pharmaceutical compositions comprising a compound of formula (I). | 2013-01-31 |
20130029975 | CGRP ANTAGONISTS - The present invention relates to new CGRP-antagonists of general formula I | 2013-01-31 |
20130029976 | PEST CONTROLLING COMPOSITION - A pest controlling composition comprising pyridalyl and indoxacarb. | 2013-01-31 |
20130029977 | Fused substituted aminopyrrolidine derivative - A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure. | 2013-01-31 |
20130029978 | NOVEL ARYL UREA DERIVATIVE - There is a need for FAAH inhibitors capable of oral administration and having excellent efficacy, particularly agents for the prevention and treatment of pain. Disclosed are novel arylurea compounds represented by formula (I), salts or solvates thereof, and pharmaceutical compositions comprising the same as an active ingredient. The pharmaceutical composition is used primarily for FAAH inhibitors, or agents for prevention and treatment of pain. | 2013-01-31 |
20130029979 | FUSED BICYCLIC COMPOUND - Fused bicyclic compound having an affinity to mineral corticoid receptor (MR), of formula [I]: | 2013-01-31 |
20130029980 | FLAVIN DERIVATIVES - The present invention relates novel flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. | 2013-01-31 |
20130029981 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS - The invention relates to substituted 2-aminoimidazoles and their imidazo[1,2- | 2013-01-31 |
20130029982 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. | 2013-01-31 |
20130029983 | AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY - The present invention is directed to methods of inhibiting a tauopathy in a patient by administration of a compound of formula I: | 2013-01-31 |
20130029984 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. | 2013-01-31 |
20130029985 | Novel Compounds - The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): | 2013-01-31 |
20130029986 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA - The present invention relates to the use of a compound of formula (I) wherein R | 2013-01-31 |
20130029987 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Diaminopyrimidine Compounds having the following structures: | 2013-01-31 |
20130029988 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 2013-01-31 |
20130029989 | TOPICAL TREATMENTS FOR PAIN - The present invention relates to novel compositions and therapeutic methods for the treatment of pain, in particular neuropathic, ischemic, muscle, arthritic or multiple sclerosis pain. The compositions include a combination of an alpha2-adrenergic agonist or a nitric oxide donor combined with a phosphodiesterase (PDE) or a phosphatidic acid (PA) inhibitor, which have been found to act together synergistically to provide effective treatment for pain, especially when administered topically. | 2013-01-31 |
20130029990 | PYRAZOLE P38 MAP KINASE INHIBITORS - There are provided inter alia compounds of formula (I): wherein R | 2013-01-31 |
20130029991 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists - The present invention relates to new sulfonamide derivatives of formula (I) | 2013-01-31 |
20130029992 | N,N-DIALKYLALKYLENYL ESTERS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF - The invention provides well defined N,N-dialkylalkenyl ester compounds for treating glaucoma or ocular hypertension. The esters of the invention are particularly advantageous due to their stability in aqueous solutions. | 2013-01-31 |
20130029993 | AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS - The present invention encompasses compounds of general formula (I) | 2013-01-31 |
20130029994 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS - The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2013-01-31 |
20130029995 | Substituted Bicyclic Aromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1). | 2013-01-31 |
20130029996 | SPECIAL COMPOSITION FOR THE USE THEREOF AS A DRUG - The present invention relates to a composition containing at least one polyphenol, at least one polyethylene glycol and/or a functional equivalent and at least one glycol ether and/or a functional equivalent for application as a medicinal product. | 2013-01-31 |
20130029997 | PYRAZINOISOQUINOLINE COMPOUNDS - This invention in one embodiment is directed to a compound of Formula Ia; | 2013-01-31 |
20130029998 | Method of Detecting and Profiling Progression of the Risk of Neurodegenerative Diseases - The present invention generally relates to methods of detecting and profiling progression of the risk of neurodegenerative diseases in a subject. In one embodiment, the method includes isolating a stem cell from cerebrospinal fluid of the subject and determining the level of H3K27 methylation within the stem cell. The subject is determined to have an increased risk of developing the neurodegenerative disease if the level of H3K27 methylation is elevated. In various embodiments, the neurodegenerative disease is Alzheimer's Disease, Parkinson's Disease or Amyotrophic Lateral Sclerosis. | 2013-01-31 |
20130029999 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE - Pyridazinyl compounds, compositions and related methods of use. | 2013-01-31 |
20130030000 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS - The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib. | 2013-01-31 |
20130030001 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS - The invention provides named compounds of formula (I), | 2013-01-31 |
20130030002 | FUNGICIDAL OXIMES AND HYDRAZONES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, | 2013-01-31 |
20130030003 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DI- AZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF - The present invention relates to a compound of formula (I), | 2013-01-31 |
20130030004 | Gyrase inhibitors and uses thereof - The present invention relates to compounds of formula I: | 2013-01-31 |
20130030005 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS - This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. | 2013-01-31 |
20130030007 | Obesity Small Molecules - The present invention relates to new therapies to treat obesity and related diseases, as well as for reducing triglyceride levels and body weight. | 2013-01-31 |
20130030008 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 2013-01-31 |
20130030009 | METHOD FOR THE TREATMENT AND/OR PREVENTION OF ORAL ALLERGIC SYMPTIONS OF THE LIPS DUE TO ORAL CONTACT WITH A FOOD ALLERGEN - A method of applying a topical preparation of at least one of a mast cell stabilizer, an antihistamine, and a leukotriene inhibitor is disclosed for prevention and/or treatment of oral allergy syndrome of the lips, including lip itchiness and/or swelling. For example, topical application of Cromolyn Sodium to the lips can be used to prevent and/or treat allergic reaction to consumption or other contact with raw fruits and/or raw vegetables. The topical administration can be performed by using applicator devices that apply at least one of a mast cell stabilizer and an antihistamine in the form of a liquid, or a gel, or a butter, or a wax-like solid, or a liposome suspension. Applicator devices can include at least one of: a roller, a brush, a sponge, a swab, a tube, a lipstick. The taste of the at least one of a mast cell stabilizer and an antihistamine can be masked by flavors. | 2013-01-31 |
20130030010 | NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF - Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions. | 2013-01-31 |
20130030011 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION - The present disclosure provides a series of compounds of the formula (I) | 2013-01-31 |
20130030012 | COMPOUNDS - The present invention relates to novel compounds that inhibit Lp-PLA | 2013-01-31 |
20130030013 | PHARMACEUTICAL PREPARATION COMPRISING PHENYLALANINE DERIVATIVE - The disclosed pharmaceutical preparation comprises a compound represented by the chemical formula (A) or a pharmaceutically acceptable salt thereof, which is dispersed in a matrix consisting of a water-soluble high molecular weight substance; and Crospovidone: | 2013-01-31 |
20130030014 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS - The present invention relates to novel N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2013-01-31 |
20130030015 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 2013-01-31 |
20130030016 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS - Method of treating a bacterial infection other than a Mycobacterial infection, using a compound of formula (Ia) or (Ib) | 2013-01-31 |
20130030017 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS - Method of treating a bacterial infection other than a Mycobacterial infection, using a compound of formula (Ia) or (Ib) | 2013-01-31 |
20130030018 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylocholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and or gastrointestinal tract disorders. | 2013-01-31 |
20130030019 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 2013-01-31 |
20130030020 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS - The invention relates to compounds of formula I: | 2013-01-31 |
20130030021 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 2013-01-31 |
20130030022 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 2013-01-31 |